Trajectory of use over time of an oral tablet and a rectal gel for HIV prevention among transgender women and men who have sex with men

References

• Ammassari, A., Trotta, M., Murri, R., Castelli, F., Narciso, P., & Noto, P. … AdICoNA Study Group. (2002). Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. JAIDS Journal of Acquired Immune Deficiency Syndromes, 31(Suppl. 3), S123–S127. doi: 10.1097/00126334-200212153-00007
   PubMed Web of Science ®Google Scholar
• Bauermeister, J., Giguere, R., Dolezal, C., Leu, C. S., Febo, I., Cranston, R. D., … Carballo-Diéguez, A. (2016). To use a rectal microbicide, first insert the applicator: Gel and applicator satisfaction among young men who have sex with men. AIDS Education and Prevention, 28(1), 1–10. doi: 10.1521/aeap.2016.28.1.1
   PubMed Web of Science ®Google Scholar
• Bauermeister, J. A., Giguere, R., Leu, C. S., Dolezal, C., Febo, I., Cranston, R. D., … Carballo-Diéguez, A. (2017). Patterns of a rectal microbicide placebo gel use in a preparatory stage for a phase I trial among young men who have sex with men. AIDS and Behavior, 22(2), 412–420. doi: 10.1007/s10461-017-1847-x
   Web of Science ®Google Scholar
• Brose, A., Scheibe, S., & Schmiedek, F. (2013). Life contexts make a difference: Emotional stability in younger and older adults. Psychology and Aging, 28(1), 148–159. doi: 10.1037/a0030047
   PubMed Web of Science ®Google Scholar
• Carballo-Diéguez, A., Giguere, R., Dolezal, C., Leu, C.-S., Balán, I., Brown IIIW., … Cranston, R. D. (2017). Preference of oral tenofovir disoproxil fumarate/emtricitabine versus rectal tenofovir reduced-glycerin 1% gel regimens for HIV prevention among cisgender men and transgender women who engage in receptive anal intercourse with men. AIDS and Behavior, 21(12), 3336–3345. doi: 10.1007/s10461-017-1969-1
   PubMed Web of Science ®Google Scholar
• Catz, S. L., Kelly, J. A., Bogart, L. M., Benotsch, E. G., & McAuliffe, T. L. (2000). Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology, 19(2), 124–133. doi: 10.1037/0278-6133.19.2.124
   PubMed Web of Science ®Google Scholar
• Corneli, A. L., Deese, J., Wang, M., Taylor, D., Ahmed, K., Agot, K., … Van Damme, L. (2014). FEM-PrEP. JAIDS Journal of Acquired Immune Deficiency Syndromes, 66(3), 324–331. doi: 10.1097/QAI.0000000000000158
   PubMed Web of Science ®Google Scholar
• Cranston, R. D., Lama, J. R., Richardson, B. A., Carballo-Diéguez, A., Kunjara Na Ayudhya, R. P., Liu, K., … MTN-017 Protocol Team. (2017). MTN-017: A rectal phase 2 extended safety and acceptability study of tenofovir reduced-glycerin 1% gel. Clinical Infectious Diseases, 64(5), 614–620.
   PubMed Web of Science ®Google Scholar
• Deutsch, M. B., Glidden, D. V., Sevelius, J., Keatley, J., McMahan, V., Guanira, J., … Mulligan, K. (2015). HIV pre-exposure prophylaxis in transgender women: A subgroup analysis of the iPrEx trial. The Lancet HIV, 2(12), e512–e519. doi: 10.1016/S2352-3018(15)00206-4
   PubMed Web of Science ®Google Scholar
• Glass, T., Battegay, M., Cavassini, M., De Geest, S., Furrer, H., & Vernazza, P., … Swiss HIV Cohort Study. (2010). Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV cohort study. Journal of Acquired Immune Deficiency Syndromes, 54(2), 197–203.
   PubMed Web of Science ®Google Scholar
• Hinkin, C. H., Hardy, D. J., Mason, K. I., Castellon, S. A., Durvasula, R. S., Lam, M. N., & Stefaniak, M. (2004). Medication adherence in HIV-infected adults. Aids (London, England), 18(1), 19–25. doi: 10.1097/00002030-200401001-00004
   PubMedGoogle Scholar
• Leu, C. S., Mabragaña, M., Giguere, R., Dolezal, C., Carballo-Diéguez, A., & McGowan, I. (2013). Use of a novel technology to track adherence to product use in a microbicide trial of short duration (MTN-007). AIDS and Behavior, 17(9), 3101–3107. doi: 10.1007/s10461-013-0549-2
   PubMed Web of Science ®Google Scholar
• Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., & Nair, G. (2015). Tenofovir-based preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine, 372(6), 509–518. doi: 10.1056/NEJMoa1402269
   PubMed Web of Science ®Google Scholar
• Rees, H., Delany-Moretlwe, S., Lombard, C., Baron, D., Panchia, R., Myer, L., … Gray, G. (2015). FACTS 001 Phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. In Conference on Retroviruses and Opportunistic Infections (CROI). Retrieved from http://www.croiconference.org/sessions/facts-001-phase-iii-trial-pericoital-tenofovir-1-gel-hiv-prevention-women
   Google Scholar
• Sineath, R. C., Finneran, C., Sullivan, P., Sanchez, T., Smith, D. K., Griensven, F. V., … Stephenson, R. (2013). Knowledge of and interest in using preexposure prophylaxis for HIV prevention among men who have sex with men in Thailand. Journal of the International Association of Providers of AIDS Care (JIAPAC), 12(4), 227–231. doi: 10.1177/2325957413488184
   PubMedGoogle Scholar
• Tolley, E. E., Harrison, P. F., Goetghebeur, E., Morrow, K., Pool, R., Taylor, D., … van der Straten, A. (2010). Adherence and its measurement in phase 2/3 microbicide trials. AIDS and Behavior, 14(5), 1124–1136. doi: 10.1007/s10461-009-9635-x
   PubMed Web of Science ®Google Scholar
• Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., … Taylor, D. (2012). Preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine, 367(5), 411–422. doi: 10.1056/NEJMoa1202614
   PubMed Web of Science ®Google Scholar
• van der Straten, A., Shiboski, S., Montgomery, E. T., Moore, J., Bruyn, G. D., Ramjee, G., … Padian, N. (2009). Patterns and predictors of adherence to diaphragm use in a phase III trial in Sub-Saharan Africa: A trajectory analysis. JAIDS Journal of Acquired Immune Deficiency Syndromes, 50(4), 419–426. doi: 10.1097/QAI.0b013e3181958511
   PubMed Web of Science ®Google Scholar